PT-141 (Bremelanotide) What the Research Actually Says: Evidence Review

Introduction

PT-141 has a more substantial evidence base than most peptides marketed by wellness clinics. The FDA approval rests on two adequately-powered phase 3 trials with over 1,200 women combined. There’s also a decade of earlier work on the molecule for erectile dysfunction that Palatin abandoned. Plus mechanistic studies in animal models going back to the 1990s.

That said, “more substantial than other peptides” doesn’t mean strong. The phase 3 efficacy is real but modest. There’s no head-to-head trial against flibanserin, the other approved drug for the same indication. There’s no completed phase 3 program in men. And long-term safety data extends only to the trial periods, not lifetime use.

This review walks through the actual trials, what they found, what they didn’t measure, and where the gaps in the evidence base lie.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Were the RECONNECT Trials?

RECONNECT was the name for two identical phase 3 trials of bremelanotide for HSDD in premenopausal women. The trials are formally labeled Study 301 and Study 302. They enrolled 1,247 women combined, randomized to bremelanotide 1.75 mg SC or placebo, used on demand for 24 weeks. Results were published as Kingsberg et al. 2019 Obstet Gynecol.

Quick Answer: RECONNECT phase 3 trials (Kingsberg et al. 2019 Obstet Gynecol) enrolled 1,247 premenopausal women with HSDD

The inclusion criteria required acquired, generalized HSDD by DSM-IV criteria, distress about the desire problem (FSDS-DAO Item 13 score of 3 or higher), and lack of response to flibanserin or willingness to try a different approach. Women with major depression, untreated thyroid disease, or significant medical illness were excluded.

The primary endpoints were change in FSFI desire score and change in FSDS-DAO distress score from baseline to end of treatment. Secondary endpoints included satisfying sexual events, FSFI total score, and patient global impression measures.

What Did the RECONNECT Trials Find on Efficacy?

Both studies hit their primary endpoints with statistical significance. The FSFI desire score improvement was 0.30 to 0.39 points greater on bremelanotide than placebo (effect size 0.21 to 0.26). The FSDS-DAO Item 13 distress score improvement was 0.30 to 0.42 points greater (effect size 0.21 to 0.28).

The clinically meaningful response analysis is more interpretable. About 25% of bremelanotide-treated women had a desire response defined as a 1.2 point increase in FSFI-D, vs 17% on placebo. The 8 percentage point absolute difference is the clearest expression of how many women benefit beyond placebo.

The number needed to treat is roughly 12. That means out of 12 women treated, 1 will benefit beyond placebo response. Compare with sildenafil for ED, where the NNT is closer to 2 to 3. PT-141 is a real drug for a real condition, but the effect size is modest.

What Did the Trials Show on Safety?

Nausea was the dominant adverse event, affecting 40% of bremelanotide-treated women vs 1% on placebo. Flushing affected 20%, injection site reactions 13%, and headache 11%. Discontinuation for adverse events was 18% on bremelanotide vs 2% on placebo.

Hyperpigmentation occurred in 1% of treated women. The cases were focal, mostly affecting the face, gums, or breasts. Most resolved over weeks to months after discontinuation, but a small subset had persistent changes.

Blood pressure rose transiently after each dose, by an average of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after injection. There were no clinically significant cardiovascular events in the trial population, but participants were screened for cardiovascular risk at entry.

What About the Earlier ED Studies?

Palatin developed PT-141 for erectile dysfunction in the early 2000s, before pivoting to HSDD. Several phase 2 trials in men with psychogenic and mild organic ED showed dose-related improvements in erectile function. Diamond et al. 2004 Int J Impot Res reported that intranasal bremelanotide at 20 mg produced clinically significant erections in 33 to 56% of doses, with placebo response around 7 to 10%.

The program was suspended after the FDA raised concerns about blood pressure increases at intranasal doses. Palatin then switched to SC administration and shifted focus to female sexual dysfunction, where on-demand dosing fits better.

The ED data establishes that PT-141 works in men through the same central mechanism that operates in women. But without a completed phase 3 program, there’s no FDA-approved indication for ED, and dosing for men remains empirical.

What Animal Data Supports the Mechanism?

The mechanistic data on melanocortin receptors and sexual function goes back to the 1990s. Pfaus and colleagues (Pfaus 2009 J Sex Med) showed in rats that MC4R agonists increase appetitive sexual behaviors (anticipatory licking, mounting attempts) more than consummatory behaviors (actual mating). This is the rodent equivalent of increased desire and motivation.

Microdialysis studies in rats show that MC4R activation in the medial preoptic area increases extracellular dopamine. The dopamine effect is required for the sexual behavior response; blocking dopamine receptors abolishes the MC4R behavioral effect.

In primates, melanocortin agonists produce penile erection through central activation. The cardiovascular effects (modest BP rise) are also observed in animal studies, validating the human findings.

What Does the Long-term Safety Data Show?

The RECONNECT trials extended to 24 weeks of use, with optional extension to 52 weeks for a subset of participants. The 52-week data shows that side effect profile remained stable over time. No new safety signals emerged.

Beyond 1 year, there’s no controlled data. Post-marketing surveillance since the 2019 approval has not revealed new concerns, but post-marketing data is observational and underpowered for rare events.

The hyperpigmentation issue gets worse with cumulative exposure based on early melanotan II observations and pharmacology. Whether the 8-dose monthly limit is sufficient to prevent meaningful hyperpigmentation over years isn’t known. Most users in clinical practice use PT-141 less frequently than the maximum, which probably reduces risk.

Key Takeaway: Side effects led to 18% trial discontinuation, dominated by nausea (40% incidence)

How Does the Evidence Compare with Flibanserin?

Flibanserin (Addyi) has its own phase 3 trial program (Thorp et al. 2014 J Sex Med; DAISY, VIOLET, BEGONIA trials). Effect sizes on the same endpoints (FSFI desire, FSDS distress, satisfying sexual events) are roughly comparable.

There’s no head-to-head trial between bremelanotide and flibanserin. The choice between them in clinical practice depends on patient preference for daily vs on-demand dosing, alcohol use (flibanserin requires abstinence), and side effect profile (flibanserin causes sedation and hypotension; bremelanotide causes nausea and BP rise).

Both drugs have had commercial struggles. Flibanserin sales were disappointing, leading to Sprout Pharmaceuticals’ acquisition and resale. Vyleesi sales have been similarly modest. Insurance coverage is the main barrier.

What Are the Major Evidence Gaps?

The biggest gap is data in men. PT-141 produces real effects on erectile function and sexual desire in men based on phase 2 work, but there’s no FDA-approved indication and no published phase 3 program in male populations. Off-label use in men is widespread but rests on biology and clinical experience rather than trials.

Postmenopausal women weren’t included in RECONNECT and represent a separate population with different physiology. Estrogen status affects melanocortin signaling, so extrapolating from premenopausal data to postmenopausal use isn’t straightforward.

Long-term safety beyond 1 year isn’t established. Cumulative hyperpigmentation, sustained cardiovascular effects, and any chronic CNS effects of repeated melanocortin activation haven’t been adequately studied.

What About Combination Therapy Evidence?

No randomized trial has tested PT-141 with other sexual function drugs. The combination with PDE5 inhibitors in men is biologically plausible (central plus peripheral mechanisms) but uncharacterized. The combination with testosterone replacement is similarly untested.

Combination with GLP-1 medications (semaglutide, tirzepatide) is increasingly common in wellness practice because both classes are popular. No trial data supports this combination.

Combination with antidepressants (especially SSRIs that cause sexual dysfunction) has theoretical interest but no controlled evidence.

What’s Coming in the PT-141 Research Pipeline?

Palatin has continued to develop melanocortin receptor agonists for other indications. Setmelanotide (Imcivree) is an MC4R-selective agonist FDA-approved for rare genetic obesity syndromes (POMC deficiency, LEPR deficiency, Bardet-Biedl syndrome). It’s a different molecule but the same target class.

PL9643 is a newer Palatin melanocortin agonist in development for dry eye disease. The eye indication uses peripheral melanocortin effects without significant CNS exposure, theoretically avoiding the sexual function and BP effects.

For sexual indications specifically, the active development is in oral or sublingual MC4R agonists that might offer better convenience than SC PT-141. Nothing is close to FDA approval.

What Should Patients Take From This Evidence?

PT-141 is a real drug with a real effect. The efficacy is modest but meaningful for some women with HSDD, where treatment options are limited. The number needed to treat of 12 reflects realistic expectations.

The side effect burden is significant. Nausea affects almost half of users, and 18% discontinued for adverse events in trials. Hyperpigmentation is rare but can be permanent. Blood pressure effects rule out the drug for people with cardiovascular risk.

Off-label use in men is supported by biology and phase 2 data but lacks phase 3 validation. Off-label use in postmenopausal women similarly extrapolates beyond trial populations.

Bottom line: No randomized data exists on combination with PDE5 inhibitors, GLP-1 medications, or testosterone replacement

FAQ

Has Bremelanotide Been Studied in Postmenopausal Women?

The RECONNECT trials enrolled only premenopausal women. Postmenopausal use is off-label. Limited additional data exists, but the FDA-approved indication is restricted to premenopausal women with acquired HSDD.

What’s the Largest Trial of PT-141 to Date?

The combined RECONNECT trials (Study 301 plus Study 302, Kingsberg et al. 2019 Obstet Gynecol) enrolled 1,247 women. This represents the largest phase 3 program for PT-141. Smaller earlier phase 2 trials in men with ED added several hundred participants total.

Is There Any Data on PT-141 for Low Libido in Men with Normal Testosterone?

There’s no randomized trial data specifically in men with low libido and normal testosterone. The early ED studies enrolled men based on erectile function, not desire. Clinical experience in wellness practices suggests PT-141 can improve desire in eugonadal men, but the evidence is anecdotal.

What Does the FDA Review of Bremelanotide Say About Long-term Safety?

The FDA approved bremelanotide based on 24-week trial data with a 52-week extension. The labeling reflects safety established over that period. Long-term use beyond the trial duration isn’t directly supported by the data.

Did the Trials Measure Improvement in Satisfying Sexual Events?

Yes. Number of satisfying sexual events per month was a secondary endpoint. Both trials showed numerical improvements on bremelanotide but didn’t reach statistical significance for this measure, possibly because the on-demand dosing pattern meant not every sexual encounter involved drug use.

What Was the Placebo Response in the Trials?

Placebo response was substantial, as is typical in sexual function trials. About 17% of placebo-treated women had a clinically meaningful desire response. The bremelanotide-placebo difference (8 percentage points) is the relevant efficacy signal, not the absolute response rate.

How Was Hyperpigmentation Defined in the Trials?

Hyperpigmentation was reported as an adverse event when participants or investigators noted visible skin darkening. It wasn’t systematically assessed with photography or quantitative methods. The 1% incidence is based on self-report and clinical observation, which likely underestimates milder cases.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.